Clinical Trial

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

Study acronym: DIAGNO-KA
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations. The distinctive feature of these actinic keratoses is that some progress into skin cancers known as cutaneous carcinomas, while others regress spontaneously; currently, there is no way to distinguish between them, either through clinical observation or biological methods. The goal of the Diagno-KA project is to develop a diagnostic test that would distinguish between actinic keratoses that progress to cancer-so they can be surgically removed early (before they become severe and metastasize)-and those that regress, thereby avoiding unnecessary surgical intervention (to prevent scarring).
Trial Details
NCT Number NCT07624981
Lead Sponsor Centre Hospitalier Régional Metz-Thionville
Conditions Skin Cancer, Diagnostic
Enrollment 140 participants
Start Date 2026-02-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03